We therefore generated the methylation profiles of seven RMC samples, three of which had been previously published in Jia et al. [9], and compared the hitherto unexplored methylation landscape of these tumors to other renal tumors (papillary renal cell carcinoma, clear cell carcinoma) and malignant rhabdoid tumors as well as epithelioid sarcomas, constituting two prototypically SMARCB1 aberrant entities. This evidence concerns the gene SMARCB1 and kidney neoplasm.